Van den Bent, M. J., Smits, M., Reijneveld, J., French, P., Clement, P., Vos, F., . . . Idbaih, A. (2018). Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): A randomised controlled phase 2 EORTC trial. The lancet. Oncology, 19(9), . https://doi.org/10.1016/S1470-2045(18)30362-0
Chicago-Zitierstil (17. Ausg.)Van den Bent, Martin J., et al. "Bevacizumab and Temozolomide in Patients with First Recurrence of WHO Grade II and III Glioma, Without 1p/19q Co-deletion (TAVAREC): A Randomised Controlled Phase 2 EORTC Trial." The Lancet. Oncology 19, no. 9 (2018). https://doi.org/10.1016/S1470-2045(18)30362-0.
MLA-Zitierstil (9. Ausg.)Van den Bent, Martin J., et al. "Bevacizumab and Temozolomide in Patients with First Recurrence of WHO Grade II and III Glioma, Without 1p/19q Co-deletion (TAVAREC): A Randomised Controlled Phase 2 EORTC Trial." The Lancet. Oncology, vol. 19, no. 9, 2018, https://doi.org/10.1016/S1470-2045(18)30362-0.